1. Scrip
  2. >>Business

Dupixent Dip Dogs Sanofi Efforts To Deal With Diabetes Decline

 
• By Kevin Grogan

Although sales of the closely-watched atopic dermatitis drug Dupixent disappointed in the first quarter, the French major sees the fall as an inventory-related blip and has high hopes that the therapy, as well as the contribution of recently acquired Bioverativ, will help fill the revenue hole left by Lantus.

Twist and turns of a modern steel roller coaster.
Bumpy ride but Sanofi expects a return to growth soon • Source: Shutterstock

Sanofi is hoping for a stronger second half of 2018 after posting a first-quarter sales decrease due to unfavorable exchange rates and weaker sales of the atopic dermatitis drug Dupixent (dupilumab), a drug the French group hopes will be instrumental in offsetting the decline of its diabetes franchise.

Dupixent sales came in at €107m (€95m in the US), some way off consensus estimates of €144m and down from €118m in the fourth quarter

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.